Company / Operating Income
Cullinan Therapeutics, Inc. Operating Income History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$196.9M
FY2024
5-year range
-$196.9M / $144.6M
FY2020-FY2024
Trend
-3.1%
vs FY2023
Sector context
#143 of 204
Health Care
What the data says
At -$197M, Cullinan Therapeutics, Inc.'s operating income ranks #143 of 204 in the Health Care sector. Declined from $145M to -$197M over the past 2 years.
Based on SEC 10-K filings.
-$197M in FY2024.
Declined from $145M to -$197M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#143 of 204 in Health CareTop 70% of 204This company -$196.9M Sector average $107.8M
▼
-282.8% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 3.1% year-over-year.
- Ranks #143 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$196.9M | -3.1% |
| FY2023 | -$191.1M | -232.1% |
| FY2022 | $144.6M | +339.7% |
| FY2021 | -$60.3M | +0.0% |
| FY2020 | -$60.3M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026